-
Sector Analysis
Parkinson's Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which...
-
Sector Analysis
Type 1 Diabetes in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033. This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report...
-
Sector Analysis
Progressive Supranuclear Palsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Progressive Supranuclear Palsy therapeutics. GlobalData epidemiologists estimate that there will be 263,657 diagnosed prevalent cases of PSP in 2024, which is expected to increase to 268,041 diagnosed prevalent cases by 2029. Currently, there are no approved treatments in the PSP market. The PSP pipeline holds 28 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and seven assets in Phase II...
-
Sector Analysis
Hyperlipidemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hyperlipidemia therapeutics. GlobalData epidemiologists estimate 128,720,003 total prevalent cases of high low-density lipoprotein C (LDL-C) with high triglycerides (TG) in 2024, which is expected to increase to 133,846,798 total prevalent cases in 2029. Most of the marketed hyperlipidemia assets, including both innovator molecules and generic molecules, are enzyme inhibitors, A total of 207 molecules are in development for hyperlipidemia, including 15 drugs in the pre-registration stage,...
-
Analyst Opinions
Unicorn Quest - Innovators in Medical and Pharma
GlobalData's Startup Series report, "Unicorn Quest - Innovators in Medical and Pharma," highlights startups poised to become unicorns in the medical and pharma sectors. It explores how advancements such as AI-driven diagnostics, gene editing, synthetic biology, and personalized healthcare solutions help address unmet medical needs and enhance precision medicine. The report provides insights into startups' growth potential, innovation strategies, and impact, enabling stakeholders to identify promising companies and understand their contributions to the evolving medical and pharmaceutical landscapes. Amidst global...
-
Sector Analysis
Human Immunodeficiency Virus (HIV) Epidemiology Analysis and Forecast to 2033
Discovered in 1983, human immunodeficiency virus (HIV) is an RNA virus that reverse transcribes itself into the human host’s DNA and produces lifelong infection. HIV primarily infects cells with CD4+ antigen, such as T-cells and macrophages, two essential white blood cell types (Swinkels et al., 2024) During the acute stage of infection, HIV destroys these CD4+ cells, which allows for the transmission of the virus, opportunistic infections, and the eventual development of AIDS (NIH, 2021; NIH, 2024). Symptoms occur within...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) - Global Clinical Trials Review, 2024" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Obstructive Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Obstructive Sleep Apnea - Global Clinical Trials Review, 2024" provides an overview of Obstructive Sleep Apnea Clinical trials scenario. This report provides top line data relating to the clinical trials on Obstructive Sleep Apnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Candidiasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Candidiasis - Global Clinical Trials Review, 2024" provides an overview of Candidiasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Candidiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Febrile Neutropenia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Febrile Neutropenia - Global Clinical Trials Review, 2024" provides an overview of Febrile Neutropenia Clinical trials scenario. This report provides top line data relating to the clinical trials on Febrile Neutropenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.